A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 501–600 of 999
Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?
Kallenberg, C. G. M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202195 · Cited by 20
“At 18 months no differences were seen in the occurrence of relapses nor in adverse events.(8) Also, renal function and scores for disease activity did not differ between both arms.”
BackgroundThe eye is a common site of granulomatosis with polyangiitis. A collaborative study
Dammacco, R., Biswas, J., Mohanan-Earatt, A., Lisch, W., Zito, F. A., Rubini, G., Manno, C., Cicco, S., Alessio, G., & Dammacco, F. (2023) · BMC Ophthalmology · doi:10.1186/s12886-022-02743-x · Cited by 20
Samson, M., Devilliers, H., Thietart, S., Charles, P., Pagnoux, C., Cohen, P., Karras, A., Mouthon, L., Terrier, B., Puéchal, X., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002953 · Cited by 24
[Wegener's granulomatosis: diagnosis and treatment].
Lastra, O. L. V., Olvera-Acevedo, A., McDonal-Vera, A., Pacheco-Ruelas, M., & Gayosso-Rivera, J. (2009) · PubMed · Cited by 20
Orbital Wegener’s granulomatosis: a case report and review of the literature
Vischio, J., & McCrary, C. T. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0949-2 · Cited by 20
Twenty-five years of European Union collaboration in ANCA-associated vasculitis research
Jayne, D. R. W., & Rasmussen, N. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv060 · Cited by 20
“Experience of shorter cyclophosphamide courses in renal vasculitis and an appreciation, following the discovery of ANCA, that the renal lesions of GPA and MPA were similar, inspired study of the two subgroups together in the CYCAZAREM trial (CYClophosphamide or AZAthioprine for REMission) [4].”
BackgroundSelf-citationAntineutrophil cytoplasmic antibody-associated vasculitis and malignancy
Trejo, M. A. C. W., Bajema, I. M., & van Daalen, E. E. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000448 · Cited by 20
Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies
Navarro-Mendoza, E., & Tobón, G. J. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0736-2 · Cited by 20
Naumovic, R. T., Jovanovic, D. B., Pavlović, S., Stošović, M., Marinković, J., & Basta-Jovanović, G. (2010) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2010.10.009 · Cited by 20
Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis
Chen, T. K., Murakami, C. A., Manno, R., & Geetha, D. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.03.008 · Cited by 20
“Potential complications include infection, leukopenia, hemorrhagic cystitis, and malignancy, among others [5,11,14].”
Jennette, J. C., & Falk, R. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05876-6.00024-1 · Cited by 20
Vasculitis in the Geriatric Population
Langford, C. A. (2005) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2005.02.011 · Cited by 20
“Patients with MPA should initially be treated with CYC 2 mg/kg/d and prednisone 1 mg/kg/d, with transition to a less toxic maintenance agent after remission as discussed for WG [65,72,73].”
BackgroundInfluentialMiyazaki, Y., Nakayamada, S., Kubo, S., Ishikawa, Y., Yoshikawa, M., Sakata, K., Iwata, S., Miyagawa, I., Nakano, K., & Tanaka, Y. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02215-x · Cited by 19
A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody
Xu, J., Yang, C.-H., Chen, X.-Y., Li, X.-H., Dai, M., & Xiao, S. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.7012 · Cited by 19
Sriskandarajah, S., Aasarød, K., Skrede, S., Knoop, T., Reisæter, A. V., & Bjørneklett, R. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv008 · Cited by 19
“This advent significantly improved prognosis, but morbidity and mortality remained high for several reasons [4–9].”
BackgroundKnight, A., Hallenberg, H., & Baecklund, E. (2013) · Clinical Rheumatology · doi:10.1007/s10067-013-2351-y · Cited by 19
“Maintenance treatment is usually given with methotrexate (MTX), azathioprine (AZA) or mycophenolate mofetil (MMF), but as at least 50 % of patients have one or several relapses, repeated induction treatment is often necessary with the risk of high cumulative doses of CY [4, 5].”
BackgroundImmunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis
Neumann, I. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa035 · Cited by 20
New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis
Nozaki, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631055 · Cited by 21
Turow, A., Yong, T. Y., Fok, J. S., & Li, J. Y. Z. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6962 · Cited by 19
“Azathioprine is widely used as a maintenance therapy in vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens (ANCA) after a trial demonstrated that azathioprine is as effective as cyclophosphamide in the prevention of relapse and has fewer adverse-effects (1).”
BackgroundInfluentialA case of ANCA-associated vasculitis presenting with calf claudication
Kim, M. Y., Bae, S. Y., Lee, M., Chung, H.-J., Lee, J., Ahn, J. K., Cha, H., & Koh, E. (2010) · Rheumatology International · doi:10.1007/s00296-010-1469-3 · Cited by 19
Roger, E. K. (2004) · Frontiers in bioscience · doi:10.2741/1259 · Cited by 26
Outcome of ANCA-Associated Primary Renal Vasculitis in Miyazaki Prefecture
Uezono, S., Sato, Y., Hara, S., Hisanaga, S., Fukudome, K., Fujimoto, S., Nakao, H., Kitamura, K., Kobayashi, S., Suzuki, K. T., et al. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6371 · Cited by 19
“Reports indicate that about 10% of ANCA-negative patients are found among those with pauci-immune crescentic glomerulonephritis or primary renal vasculitis (10, 14, 24, 28).”
BackgroundResultSmall-vessel vasculitis: Therapeutic management
Langford, C. A. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0052-8 · Cited by 19
“Most of the therapeutic data in MPA has come from studies in which it was combined with WG. Although clinical and histologic similarities exist between MPA and WG, MPA differs from WG in that it lacks granuloma formation, has a predominance of myeloperoxidase- rather than proteinase 3–ANCA antigen specifi city, and th…”
BackgroundMethodInfluentialLin, W., Chen, M., & Zhao, M. (2009) · Autoimmunity · doi:10.1080/08916930802668594 · Cited by 19
“Since the employment of corticosteroids and cyclophosphamide, remission can be achieved in most of the patients [8].”
BackgroundLionaki, S., Marinaki, S., Liapis, G., Kalaitzakis, E., Fragkioudaki, S., Kalogeropoulos, P. G., Michelakis, I., Goules, A. V., Tzioufas, A. G., & Boletis, J. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.043 · Cited by 20
Maintenance of clinical remission in ANCA-associated vasculitis
Luqmani, R. A. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.188 · Cited by 19
Hiemstra, T. F., Jones, R. B., & Jayne, D. R. W. (2010) · Nephron Clinical Practice · doi:10.1159/000314543 · Cited by 18
Self-citationRespiratory System Involvement??in Antineutrophil??Cytoplasmic-Associated Systemic Vasculitides
Pesci, A., & Manganelli, P. (2007) · Drugs in R&D · doi:10.2165/00126839-200708010-00003 · Cited by 18
Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Calabrese, L. H., Molloy, E. S., & Duna, G. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10082-8 · Cited by 18
Fever-Like Temperatures Affect Neutrophil NF-κB Signaling, Apoptosis, and ANCA-Antigen Expression
Kettritz, R., Choi, M., Salanova, B., Wellner, M., Rolle, S., & Luft, F. C. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090948 · Cited by 20
Ikeda, S., Arita, M., Misaki, K., Kashiwagi, Y., Ito, Y., Yamada, H., Hotta, M., Nishiyama, A., Ito, A., Noyama, M., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0068-1 · Cited by 17
“Relapses are more common in patients with GPA (25 to 80 % of patients) than in those with MPA, in whom relapse has been reported in 8 % at 18 months [32].”
BackgroundTherapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis
Bloom, J. L., Langford, C. A., & Wechsler, M. E. (2023) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2023.03.006 · Cited by 17
Magri, S., Ugarte-Gil, M. F., Brance, M. L., Flores-Suárez, L. F., Fernández-Ávila, D. G., Scolnik, M., Sato, E. I., de Souza, A. W. S., Rivera, L. M. S., Babini, A. M., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00128-5 · Cited by 22
Update on the treatment of ANCA associated vasculitis
Smith, R. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.04.008 · Cited by 18
Twenty-five years of RENHIS: a history of histopathological studies within EUVAS
van Daalen, E., Ferrario, F., Noël, L., Waldherr, R., Hagen, E. C., Bruijn, J. A., & Bajema, I. M. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv035 · Cited by 17
Self-citationCancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study
Sriskandarajah, S., Bostad, L. H., Myklebust, T. Å., Møller, B., Skrede, S., & Bjørneklett, R. O. (2017) · International Journal of Nephrology · doi:10.1155/2017/6013038 · Cited by 18
Savige, J., Trevisin, M., & Pollock, W. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.02.016 · Cited by 17
Monti, S. M., Delvino, P., Riboli, M., Rebuffi, C., Xoxi, B., Silvestri, A. D., & Montecucco, C. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab267 · Cited by 17
McDermott, G. C., Fu, X., Cook, C., Ahola, C., Doliner, B., Hanberg, J. S., Stone, J. H., Choi, H. K., Zhang, Y., & Wallace, Z. S. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2022-222439 · Cited by 21
“[6, 38,39] This is likely multifactorial, including the MPO-ANCA predominance of our cohort, which has a lower risk of flare[40], as well as the enrollment of patients with relapse into some clinical trials and therefore selection for patients at higher risk of relapse, or other factors.”
Induction and maintenance therapy in ANCA‐associated systemic vasculitis
Menahem, S. A., Hiremagalur, B., Mudge, D. W., Toussaint, N. D., & Walters, G. D. (2008) · Nephrology · doi:10.1111/j.1440-1797.2008.00995.x · Cited by 17
Skeik, N., Hari, G., & Nasr, R. (2019) · Rheumatology International · doi:10.1007/s00296-019-04343-3 · Cited by 17
Pagnoux, C. (2008) · La Presse Médicale · doi:10.1016/j.lpm.2008.06.016 · Cited by 17
How can patient care be improved beyond medical treatment?
Pagnoux, C., & Guillevin, L. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.11.005 · Cited by 17
Vasculitis in the Geriatric Population
Langford, C. A. (2007) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.12.002 · Cited by 17
Treatment of ANCA‐associated systemic small‐vessel vasculitis
Jayne, D. R. W. (2009) · Apmis · doi:10.1111/j.1600-0463.2009.02470.x · Cited by 19
Self-citationHirohama, D., Hoshino, J., Hasegawa, E., Yamanouchi, M., Hayami, N., Suwabe, T., Sawa, N., Takemoto, F., Ubara, Y., Hara, S., et al. (2010) · Modern Rheumatology · doi:10.1007/s10165-010-0339-x · Cited by 17
GRANULOMATOUS VASCULITIS, GIANT CELL ARTERITIS, AND SARCOIDOSIS
Lindsley, C. B., & Laxer, R. M. (2005) · Elsevier eBooks · doi:10.1016/b978-1-4160-0246-8.50032-2 · Cited by 18
Interventions for renal vasculitis in adults
Walters, G. D., Willis, N. S., & Craig, J. C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003232.pub2 · Cited by 17
Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach
Baweja, S., Wiggins, K., Lee, D., Blair, S., Fraenkel, M. B., & McMahon, L. P. (2010) · Journal of Artificial Organs · doi:10.1007/s10047-010-0529-5 · Cited by 16
“Although cyclophosphamide and corticosteroids lead to remission in over 90% of cases [50, 51], and recent studies showed similar outcome with the rituximab-based regime [52, 53], patients with advanced renal failure have poorer outcomes with only 50% surviving with independent renal function at 1 year [54, 55].”
ResultSpringer, J. M., Kalot, M. A., Husainat, N. M., Byram, K., Dua, A. B., James, K. E., Lin, Y. C., Turgunbaev, M., Villa‐Forte, A., Abril, A., et al. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11230 · Cited by 16
“After remission is achieved, less toxic maintenance regimens are utilized to prevent relapses while minimizing toxicities (6).”
BackgroundEconomic impact of giving land to refugees
Zhu, H., Gupta, A., Filipski, M., Valli, J., Gonzalez‐Estrada, E., & Taylor, J. E. (2023) · American Journal of Agricultural Economics · doi:10.1111/ajae.12371 · Cited by 17
First-line immunosuppression in neuromuscular diseases
Foster, M. A., Lunn, M. P., & Carr, A. S. (2023) · Practical Neurology · doi:10.1136/pn-2023-003708 · Cited by 16
Assessment of systemic vasculitis
Miller, A., Basu, N., & Luqmani, R. A. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.07.001 · Cited by 16
Yumura, W., Kobayashi, S., Suka, M., Hayashi, T., Ito, S., Nagafuchi, H., Yamada, H., Ozaki, S., & for the JMAAV Study Group (2014) · Modern Rheumatology · doi:10.3109/14397595.2013.854075 · Cited by 16
“BVAS has been used in more than 10 published therapeutic studies on vasculitis by various groups over the past 5 years [13–22].”
MethodSuzuki, Y., Takeda, Y., Sato, D. S., Kanaguchi, Y., Tanaka, Y., Kobayashi, S., Suzuki, K. T., Hashimoto, H., Ozaki, S., Horikoshi, S., et al. (2009) · Modern Rheumatology · doi:10.1007/s10165-009-0239-0 · Cited by 16
Cornec, D., Gall, É. C.-L., & Specks, U. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw384 · Cited by 17
Veltri, N. L., Hladunewich, M., Bhasin, A. A., Garland, J. S., & Thomson, A. B. R. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy011 · Cited by 16
Suka, M., Hayashi, T., Kobayashi, S., Ito, S., Yumura, W., & Ozaki, S. (2012) · Modern Rheumatology · doi:10.1007/s10165-012-0602-4 · Cited by 16
Treatment strategies for vasculitis that affects the nervous system
Broussalis, E., Trinka, E., Kraus, J., McCoy, M. R., & Killer‐Oberpfalzer, M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.009 · Cited by 16
“and Jayne, D. (2011) Plasma exchange in the treatment of Wegener’s”
Wilde, B., Mertens, A. E. C. S., Arends, S., Rouhl, R. P. W., Bijleveld, R., Huitema, J. J., Timmermans, S. A. M. E. G., Damoiseaux, J. G. M. C., Witzke, O., Duijvestijn, A. M., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1044-8 · Cited by 19
“Treatment with immunosuppressive drugs reduces mortality significantly but needs to be continued even after remission has been achieved, and despite treatment, relapses occur frequently [2].”
BackgroundSelf-citationRetiform purpura: Workup and therapeutic considerations in select conditions
Georgesen, C., Fox, L. P., & HARP, J. L. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.113 · Cited by 16
Biomarkers in ANCA-Associated Vasculitis
Lally, L., & Spiera, R. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0363-x · Cited by 16
Matsumoto, Y., Sada, K., Otsuka, F., Takano, M., Toyota, N., Sugiyama, K., Wakabayashi, H., Kawabata, T., & Makino, H. (2011) · Rheumatology International · doi:10.1007/s00296-011-2136-z · Cited by 16
“the mean rate of remission induction during the Wrst 6 months was 87% (range, 68–93%) [15–19, 24] and the rate of relapse during the Wrst 12 months was approximately 10% [16].”
BackgroundResultSpecks, U. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79.s3.02 · Cited by 15
ANCA associated vasculitis in patients from Saudi Arabia
Arfaj, A. S. A., & Khalil, N. A. (2018) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.341.13881 · Cited by 15
Koening, C. L. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88746 · Cited by 16
Expert Perspective: Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Patel, N. J., & Stone, J. H. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42114 · Cited by 17
Watanabe, K., Tani, Y., Kimura, H., Tanaka, K., Hayashi, Y., Asahi, K., Sato, K., Sato, M., Matsushima, M., Nakayama, M., et al. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.7727 · Cited by 15
“Furthermore, mortality of MPA among the elderly is higher than GPA (19, 20), therefore, earlier detection and initiation of treatment is very important.”
BackgroundInfluentialOutcome Measures in ANCA-associated Vasculitis
Suppiah, R., Robson, J. C., & Luqmani, R. A. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.04.001 · Cited by 15
Oristrell, J., Bejarano, G., Jordana, R., Monteagudo, M., Marí-Alfonso, B., Casanovas, A., & Tolosa-Vilella, C. (2009) · The Open Respiratory Medicine Journal · doi:10.2174/1874306400903010094 · Cited by 15
“For all these reasons, research into the treatment of WG is still ongoing and many treatment protocols have been tested in attempts to reduce the toxicity associated with the prolonged use of alkylating agents [5, 8, 9].”
BackgroundCorticosteroids in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Keller, S. F., & Miloslavsky, E. M. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.010 · Cited by 17
Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis
Singer, O., & McCune, W. J. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000382 · Cited by 15
Roccatello, D. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.015 · Cited by 15
Newer therapies for vasculitis
Hiemstra, T. F., & Jayne, D. R. W. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.01.005 · Cited by 15
Self-citationMycophenolate mofetil in systemic vasculitis
D’Cruz, D. P. (2005) · Lupus · doi:10.1191/0961203305lu2120oa · Cited by 15
Eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss syndrome): where are we now?
Groh, M., Pagnoux, C., & Guillevin, L. (2015) · European Respiratory Journal · doi:10.1183/13993003.00963-2015 · Cited by 15
L52. Vasculitis treatment: Is it time to change the standard of care for ANCA-associated vasculitis?
Hoffman, G. S. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.01.047 · Cited by 14
Epidemiology of ANCA associated vasculitis
Koldingsnes, W., & Nossent, J. C. (2009) · Norsk Epidemiologi · doi:10.5324/nje.v18i1.62 · Cited by 14
“The relapse rate in MPA is lower than in WG (78).”
BackgroundChan, M., & Luqmani, R. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902946401 · Cited by 14
“Pulsed cyclophosphamide is associated with reduced morbidity related to leucopenia and infection, chiefly due to a lower cumulative dose of cyclophosphamide compared with continuous daily oral dosing [36].”
BackgroundMethodInfluentialPagnoux, C., Quéméneur, T., Ninet, J., Perrodeau, É., Diot, É., Kyndt, X., de Wazières, B., Reny, J., Puéchal, X., Berruyer, P. Y. L., et al. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.02.069 · Cited by 14
Utilisation de l’azathioprine dans le traitement de l’artérite à cellules géantes
Boureau, A., Faucal, P. D., Espitia, O., Decker, L. D., & Agard, C. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.03.007 · Cited by 18
Crnogorac, M., Horvatić, I., Torić, L., Ljubanović, D. G., Tišljar, M., & Gales̃ić, K. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1610-2 · Cited by 14
“In the last decades, immunosuppressive therapy with cyclophosphamide (CYC) and glucocorticoids (GC), with well-established protocols by randomized control trials [9, 10], has led to dramatic improvement in renal and patient Abstract Purpose To evaluate significance of clinical and histopathological prognostic factors…”
BackgroundTargeted immunotherapy strategies in ANCA-associated vasculitis
Puéchal, X. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.09.002 · Cited by 14
Long-term follow-up of microscopic polyangiitis, 17-year experience at a single center
Borao‐Cengotita‐Bengoa, M., Corral-Gudino, L., del Pino‐Montes, J., & Lerma-Márquez, J. L. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.09.005 · Cited by 14
“Recently, themortality rate of MPA was described as being higher, [5–7] and MPA was described as having a lower relapse rate [8–10].”
BackgroundWu, Z., Wu, Q., Xu, J., Chen, S., Sun, F., Li, P., Bai, Y., Zheng, W., Chen, H., Zhang, F., et al. (2015) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12561 · Cited by 15
ANCA vasculitis: time for a change in treatment paradigm? Not yet
Ntatsaki, E., Mooney, J., & Watts, R. A. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker002 · Cited by 14
de Souza, A. W. S., Calich, A. L., Mariz, H. D. A., Ochtrop, M. L. G., Bacchiega, A. B. S., Ferreira, G. A., Rêgo, J., Perez, M. O., Pereira, R. M. R., Bernardo, W. M., et al. (2017) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2017.05.002 · Cited by 14
Suzuki, Y., Takeda, Y., Sato, D. S., Kanaguchi, Y., Tanaka, Y., Kobayashi, S., Suzuki, K. T., Hashimoto, H., Ozaki, S., Horikoshi, S., et al. (2010) · Modern Rheumatology · doi:10.3109/s10165-009-0239-0 · Cited by 14
Morishita, K. A., Brown, K. L., & Cabral, D. A. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000203 · Cited by 14
“The current standard of care in adults is to use azathioprine (AZA) for at least 18 months following remission induction [28].”
Traitement des vascularites systémiques associées aux ANCA
Guillevin, L., & Pagnoux, C. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.01.029 · Cited by 14
Seta, N., Tajima, M., Kobayashi, S., Kawakami, Y., Hashimoto, H., & Kuwana, M. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0109-1 · Cited by 14
Glomerular and Tubulointerstitial Diseases
Beck, L. H., & Salant, D. J. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.01.002 · Cited by 19
Carpenter, D. M., Pepper, J. K., DeVellis, R. F., Hogan, S. L., & Jordan, J. M. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100808 · Cited by 18
Treatment of ANCA-associated systemic vasculitis.
Belmont, M. H. (2006) · PubMed · Cited by 14
Current pharmacotherapy for the treatment of crescentic glomerulonephritis
Tam, F. W. K. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.11.1353 · Cited by 14
“[12] Randomised controlled trial General vasculitis, serum creatinine ≤ 500 μM/l (n = 155) Maintenance: CYCAZAREM, CYC versus AZA plus Pred 18 No difference in relapse rate”
BackgroundMethodWegener Granulomatosis: A Case Report and Update
Mubashir, E., Ahmed, M. M., Hayat, S., Latif, S., Heldmann, M. G., & Berney, S. M. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000232210.04881.d3 · Cited by 14
“7% in the azathioprine and cyclophosphamide groups, respectively (CYCAZAREM).(18) The French vasculitis study group recently presented preliminary data from a prospective multicenter randomized trial comparing azathioprine (2 mg/kg/d) with methotrexate (0.”
BackgroundPagnoux, C., Guilpain, P., & Guillevin, L. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.01.030 · Cited by 14
Various Forms of Life in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Hogan, S. L., Falk, R. J., Nachman, P. H., & Jennette, J. C. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00019 · Cited by 14
Langford, C. A. (2004) · PubMed · Cited by 14
Quality of life of patients treated for giant cell arteritis: a case-control study
Jobard, S., Magnant, J., Blasco, H., Ferreira-Maldent, N., Griffoul, I., Diot, É., & Maillot, F. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3619-4 · Cited by 13
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.